Cargando…

Resistance to Cell Death in Mucinous Colorectal Cancer—A Review

SIMPLE SUMMARY: Mucinous colorectal cancer is characterised by abundant mucin glycoprotein production and is associated with resistance to chemotherapy-based treatments. This review outlines mechanisms for cell death resistance present in mucinous colorectal cancer including glycoprotein interaction...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Connell, Emer, Reynolds, Ian S., McNamara, Deborah A., Burke, John P., Prehn, Jochen H. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003305/
https://www.ncbi.nlm.nih.gov/pubmed/33808549
http://dx.doi.org/10.3390/cancers13061389
_version_ 1783671658635067392
author O’Connell, Emer
Reynolds, Ian S.
McNamara, Deborah A.
Burke, John P.
Prehn, Jochen H. M.
author_facet O’Connell, Emer
Reynolds, Ian S.
McNamara, Deborah A.
Burke, John P.
Prehn, Jochen H. M.
author_sort O’Connell, Emer
collection PubMed
description SIMPLE SUMMARY: Mucinous colorectal cancer is characterised by abundant mucin glycoprotein production and is associated with resistance to chemotherapy-based treatments. This review outlines mechanisms for cell death resistance present in mucinous colorectal cancer including glycoprotein interactions with cell survival and cell apoptotic pathways. Further mechanisms are explored, including alterations in the expression of chemotherapy metabolism and resistance genes. This review identifies directions for future investigation of mucinous colorectal cancer and novel treatment strategies. ABSTRACT: Mucinous colorectal cancer (CRC) is estimated to occur in approximately 10–15% of CRC cases and is characterized by abundant extracellular mucin. Mucinous CRC is frequently associated with resistance to apoptosis. Inferior prognosis is observed in mucinous CRC, particularly in rectal cancer and metastatic cases. Mucins are heavily glycosylated secretory or transmembrane proteins that participate in protection of the colonic epithelium. MUC2 overexpression is a hallmark of mucinous CRCs. Mucinous CRC is associated with KRAS and BRAF mutation, microsatellite instability and the CpG island methylator phenotype. Mutations of the APC gene and p53 mutations which are characteristic non-mucinous colorectal adenocarcinoma are less common in mucinous CRC. Both physical and anti-apoptotic properties of mucin provide mechanisms for resistance to cell death. Mucin glycoproteins are associated with decreased expression of pro-apoptotic proteins, increased expression of anti-apoptotic proteins and increased cell survival signaling. The role for BCL-2 proteins, including BCL-X(L), in preventing apoptosis in mucinous CRC has been explored to a limited extent. Additional mechanisms opposing cell death include altered death receptor expression and altered mutation rates in genes responsible for chemotherapy resistance. The roles of alternate cell death programs including necroptosis and pyroptosis are not well understood in mucinous CRC. While the presence of MUC2 is associated with an immunosuppressive environment, the tumor immune environment of mucinous CRC and the role of immune-mediated tumor cell death likewise require further investigation. Improved understanding of cell death mechanisms in mucinous CRC may allow modification of currently used regimens and facilitate targeted treatment.
format Online
Article
Text
id pubmed-8003305
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80033052021-03-28 Resistance to Cell Death in Mucinous Colorectal Cancer—A Review O’Connell, Emer Reynolds, Ian S. McNamara, Deborah A. Burke, John P. Prehn, Jochen H. M. Cancers (Basel) Review SIMPLE SUMMARY: Mucinous colorectal cancer is characterised by abundant mucin glycoprotein production and is associated with resistance to chemotherapy-based treatments. This review outlines mechanisms for cell death resistance present in mucinous colorectal cancer including glycoprotein interactions with cell survival and cell apoptotic pathways. Further mechanisms are explored, including alterations in the expression of chemotherapy metabolism and resistance genes. This review identifies directions for future investigation of mucinous colorectal cancer and novel treatment strategies. ABSTRACT: Mucinous colorectal cancer (CRC) is estimated to occur in approximately 10–15% of CRC cases and is characterized by abundant extracellular mucin. Mucinous CRC is frequently associated with resistance to apoptosis. Inferior prognosis is observed in mucinous CRC, particularly in rectal cancer and metastatic cases. Mucins are heavily glycosylated secretory or transmembrane proteins that participate in protection of the colonic epithelium. MUC2 overexpression is a hallmark of mucinous CRCs. Mucinous CRC is associated with KRAS and BRAF mutation, microsatellite instability and the CpG island methylator phenotype. Mutations of the APC gene and p53 mutations which are characteristic non-mucinous colorectal adenocarcinoma are less common in mucinous CRC. Both physical and anti-apoptotic properties of mucin provide mechanisms for resistance to cell death. Mucin glycoproteins are associated with decreased expression of pro-apoptotic proteins, increased expression of anti-apoptotic proteins and increased cell survival signaling. The role for BCL-2 proteins, including BCL-X(L), in preventing apoptosis in mucinous CRC has been explored to a limited extent. Additional mechanisms opposing cell death include altered death receptor expression and altered mutation rates in genes responsible for chemotherapy resistance. The roles of alternate cell death programs including necroptosis and pyroptosis are not well understood in mucinous CRC. While the presence of MUC2 is associated with an immunosuppressive environment, the tumor immune environment of mucinous CRC and the role of immune-mediated tumor cell death likewise require further investigation. Improved understanding of cell death mechanisms in mucinous CRC may allow modification of currently used regimens and facilitate targeted treatment. MDPI 2021-03-19 /pmc/articles/PMC8003305/ /pubmed/33808549 http://dx.doi.org/10.3390/cancers13061389 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
O’Connell, Emer
Reynolds, Ian S.
McNamara, Deborah A.
Burke, John P.
Prehn, Jochen H. M.
Resistance to Cell Death in Mucinous Colorectal Cancer—A Review
title Resistance to Cell Death in Mucinous Colorectal Cancer—A Review
title_full Resistance to Cell Death in Mucinous Colorectal Cancer—A Review
title_fullStr Resistance to Cell Death in Mucinous Colorectal Cancer—A Review
title_full_unstemmed Resistance to Cell Death in Mucinous Colorectal Cancer—A Review
title_short Resistance to Cell Death in Mucinous Colorectal Cancer—A Review
title_sort resistance to cell death in mucinous colorectal cancer—a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003305/
https://www.ncbi.nlm.nih.gov/pubmed/33808549
http://dx.doi.org/10.3390/cancers13061389
work_keys_str_mv AT oconnellemer resistancetocelldeathinmucinouscolorectalcancerareview
AT reynoldsians resistancetocelldeathinmucinouscolorectalcancerareview
AT mcnamaradeboraha resistancetocelldeathinmucinouscolorectalcancerareview
AT burkejohnp resistancetocelldeathinmucinouscolorectalcancerareview
AT prehnjochenhm resistancetocelldeathinmucinouscolorectalcancerareview